CIK 0001719406 · Non-accelerated filer<br>Smaller reporting company
NRX Pharmaceuticals, Inc.
Sign in to watch- Ticker
- NRXP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822844431
- Phone
- 484-254-6134
- Business address
- 1201 ORANGE STREET, SUITE 600, WILMINGTON, DE, 19801
- Former names
- Big Rock Partners Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-10-21 | Flynn Patrick John Director | Grant or award · Employee Stock Option | +162,660 | 162,660 | ||
| 2022-10-21 | Hurvitz Chaim Director | Grant or award · Employee Stock Option | +162,660 | 381,083 | ||
| 2022-07-29 | Javitt Daniel C. 10% owner | Sale | −784,063 | $1.01 | $791K | 9,872,901 |
| 2022-07-01 | Javitt Daniel C. 10% owner | Gift | −2,000,000 | 10,656,964 | ||
| 2022-06-07 | Javitt Daniel C. 10% owner | Sale | −86,459 | $0.65 | $56K | 12,656,964 |
| 2022-06-06 | Javitt Daniel C. 10% owner | Sale | −115,657 | $0.67 | $77K | 12,743,423 |
| 2022-06-03 | Javitt Daniel C. 10% owner | Sale | −243,596 | $0.70 | $171K | 12,859,080 |
| 2022-06-01 | Javitt Jonathan C Chief Scientist | Purchase | +100,000 | $0.58 | $58K | 146,332 |
| 2022-06-01 | Javitt Jonathan C Chief Scientist | Purchase | +100,000 | $58.00 | $5.8M | 146,332 |
| 2022-03-08 | Besthof Robert Interim CEO | Grant or award · Employee Stock Option | +100,000 | $2.61 | $261K | 347,200 |
| 2021-09-15 | Besthof Robert Chief Comm. & Patient Officer | Sale | −40,000 | $11.76 | $470K | 23,710 |
| 2021-09-02 | Daigneault Alessandra General Counsel & Secretary | Option exercise | +18,420 | $3.07 | $57K | 18,420 |
| 2021-09-02 | Daigneault Alessandra General Counsel & Secretary | Option exercise | +13,164 | $3.07 | $40K | 31,584 |
| 2021-09-02 | Daigneault Alessandra General Counsel & Secretary | Conversion · Employee Stock Option (Right to buy) | −28,916 | $3.07 | $89K | 71,924 |
| 2021-09-02 | Daigneault Alessandra General Counsel & Secretary | Conversion · Employee Stock Option (Right to buy) | −20,666 | $3.07 | $63K | 28,934 |
| 2021-09-02 | Daigneault Alessandra General Counsel & Secretary | Grant or award · Restricted Stock Units | +10,496 | 26,101 | ||
| 2021-09-02 | Daigneault Alessandra General Counsel & Secretary | Grant or award · Restricted Stock Units | +7,502 | 33,603 | ||
| 2021-08-26 | McMaster Herbert Raymond Director | Option exercise | +18,300 | $2.22 | $41K | 18,300 |
| 2021-08-26 | McMaster Herbert Raymond Director | Conversion · Employee Stock Option (Right to buy) | −28,724 | $2.22 | $64K | 16,362 |
| 2021-08-26 | McMaster Herbert Raymond Director | Grant or award · Restricted Stock Units | +10,424 | 10,424 |
Page 3 of 6 · 108 trades